{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T09:35:16Z","timestamp":1776850516363,"version":"3.51.2"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dev Pharmacol Ther"],"abstract":"<jats:p>Objective. To assess the central nervous system side effects of chlorpheniramine\nand astemizole in children. Design. Prospective, randomized, double-\nblind cross-over study. Setting. Children were recruited from the outpatient\nallergy clinic and from respondents to an advertisement in a local\nnewspaper. The study was conducted in the outpatient clinics of the ambulatory\ncare services of the Children\u2019s Hospital of Eastern Ontario. Patients,\nParticipants. Children 8-16 years of age, with isolated allergic rhinitis\nor hay fever, were eligible for the study. We excluded children with:\n(1) chronic conditions (specifically asthma, atopic dermatitis, learning\ndisabilities, or current treatment with oral corticosteroid medication);\n(2) known allergy to the study medications; (3) recent use of any antihistamine\nmedication. One hundred and three children entered the study and\n92 completed it. Interventions. Children were stratified by age and randomly\nallocated to treatment with one of the two medication sequences.\nOver a period of 13 weeks both groups had 1 week of baseline studies, 3\nweeks of one study medication, either chlorpheniramine or astemizole, a\n6-week wash-out period and then 3 weeks of the other study medication\nfor a second treatment period. Main Outcome Measures. Attention span\n(continuous performance test), short-term auditory and visual memory\n(visual aural digit span test), visual memory for geometric shapes (Benton\nvisual retention test), motor coordination and visual-motor integration\n(grooved pegboard test), tapping speed and fine motor coordination (finger\ntapping test), physical side effects (such as sleepiness and dizziness),\nand compliance. Results. One hundred and three patients were enrolled in\nthe study, 92 (89%) completed the study. There were no significant drug\neffects on the visual retention test and the continuous performance test.\nOn the visual aural digit span test, patients treated with astemizole scored\nhigher than at baseline. There were no clinical or statistical differences in\nadverse effects between the two medications or between each medication\nand baseline. Conclusions. The two antihistamines studied had no adverse\neffects on the performance of children.<\/jats:p>","DOI":"10.1159\/000457568","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T17:08:44Z","timestamp":1502471324000},"page":"239-246","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of CNS Adverse\nEffects between Astemizole and\nChlorpheniramine in Children: A\nRandomized, Double-Blind Study"],"prefix":"10.1159","author":[{"given":"Amir","family":"Shanon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lewis","family":"Leikin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Ham Pong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2017,8,11]]},"container-title":["Developmental Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000457568","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:34:55Z","timestamp":1776846895000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000457568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000457568","archive":["Portico"],"relation":{},"ISSN":["0379-8305","2504-2505"],"issn-type":[{"value":"0379-8305","type":"print"},{"value":"2504-2505","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,11]]}}}